Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes
NCT05689424
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Type 1 Diabetes
Interventions
DRUG:
HDV-Insulin Lispro
Sponsor
University of California, San Diego
Collaborators
[object Object]